We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · March 24, 2021

ICIs Are Effective in the Treatment of Older Adults With mRCC

Journal of Geriatric Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Geriatric Oncology
Efficacy of Immune-Checkpoint Inhibitors (ICI) in the Treatment of Older Adults With Metastatic Renal Cell Carcinoma (mRCC) — An International mRCC Database Consortium (IMDC) Analysis
J Geriatr Oncol 2021 Mar 02;[EPub Ahead of Print], DV Araujo, JC Wells, AR Hansen, N Dizman, SK Pal, B Beuselinck, F Donskov, CL Gan, F Yan, B Tran, CK Kollmannsberger, G de Velasco, T Yuasa, MN Reaume, DS Ernst, T Powles, GA Bjarnason, TK Choueiri, DYC Heng, S Dudani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading